Literature DB >> 29350549

Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.

Orazio Caffo1, Antonello Veccia1, Stefania Kinspergher1, Francesca Maines1.   

Abstract

Abiraterone acetate, which targets enzymatic complexes playing a central role in steroidogenesis, demonstrated to increase survival significantly in both chemo-naive and docetaxel pretreated, becoming one of the drugs of choice for metastatic castration-resistant prostate cancer. More recently, this agent in combination to androgen deprivation therapy demonstrated to be efficacious also in metastatic castration-sensitive prostate cancer. The present review is aimed to outline the clinical development of abiraterone acetate, the pivotal trials which led to its approval for the clinical practice, new evidence about its efficacy in metastatic castration-sensitive prostate cancer, its place in the therapeutic landscape of prostate cancer and future directions of development.

Entities:  

Keywords:  abiraterone acetate; castration-resistant prostate cancer; castration-sensitive prostate cancer

Mesh：

Substances：

Year:  2018        PMID： 29350549     DOI： 10.2217/fon-2017-0430

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  Resistance to second-generation androgen receptor antagonists in prostate cancer.

Authors:  Keith T Schmidt; Alwin D R Huitema; Cindy H Chau; William D Figg
Journal:  Nat Rev Urol       Date:  2021-03-19       Impact factor: 14.432

2.  Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.

Authors:  Zeying Feng; Yaxin Liu; Yun Kuang; Shuang Yang; Jinlei Li; Ling Ye; Jie Huang; Qi Pei; Yuanyuan Huang; Guoping Yang
Journal:  Drug Des Devel Ther       Date:  2022-01-03       Impact factor: 4.162

3.  Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.

Authors:  Magali Rouyer; Stéphane Oudard; Florence Joly; Karim Fizazi; Florence Tubach; Jérémy Jove; Clémentine Lacueille; Stéphanie Lamarque; Estelle Guiard; Aurélie Balestra; Cécile Droz-Perroteau; Annie Fourrier-Reglat; Nicholas Moore
Journal:  Br J Cancer       Date:  2019-11-13       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.